Sanofi reports results from the RILECSU phase II study showing that its rilzabrutinib rapidly reduced the severity of itching caused by chronic spontaneous urticaria and significantly improved disease activity in adults.

These results were presented as a poster on Saturday at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2024 Congress in Washington, and form the basis of the Phase III program due to start in 2024.

Results from pivotal Phase III trials in the treatment of immune thrombocytopenia and Phase II trials in asthma, IgG4 disease and autoimmune hemolytic anemia are expected in 2024', adds the healthcare giant.

Copyright (c) 2024 CercleFinance.com. All rights reserved.